Cambridge Healthtech Institute’s 13th Annual

GLP1 & Oral Peptides

Obesity-Related Drug Discovery Advances

April 15-16, 2025

The promise of anti-obesity therapeutics is generating a flurry of related research and drug development in the pharmaceutical and medical research establishment. In 2021, the FDA approved the first chronic weight-loss-specific medication, Wegovy, based on agonists of the glucagon-like peptide (GLP) receptor; GLP1 agonists were originally launched for diabetes. At CHI’s GLP1 & Oral Peptides conference, leading discovery chemists will convene to share progress and innovations spurred by GLP1R agonist-focused drug development, including the development of oral peptides. We also cover obesity-related therapeutic progress beyond GLP1 peptides such as the development of small molecules and 2nd generation compounds.

Coverage will likely include:

GLP1R peptide agonists in development
GLP1R small molecule agonist progress
Anti-obesity approaches beyond GLP1 (including dual & triple agonists)
Oral peptide innovations (GLP1 and beyond)
Peptide formulation and delivery strategies relevant to discovery chemists
Constrained peptide approaches for oral bioavailability

The deadline for submission is October 7, 2024.

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

Opportunities for Participation: